Background. Currently, complete surgical resection is the only curative option for medullary thyroid cancer (MTC). Previous work has shown the Notch pathway is a potent tumor suppressor in MTC and that resveratrol activates the Notch pathway in carcinoid cancer, a related neuroedocrine malignancy. In this study, we hypothesized that the effects observed on carcinoid cells could be extended to MTC. Methods. MTC cells treated with varying doses of resveratrol were assayed for viability by the MTT (3-[4,5-dimethylthiazol-2-yl]-2,5 diphenyl tetrazolium bromide) assay. Western blot analysis for achaete-scute complex-like 1 (ASCL1), chromogranin A (CgA), full-length and cleaved caspase 3, and poly-ADP ribose polymerase (PARP) was performed. Quantitative real-time polymerase chain reaction (qPCR) was used to measure relative mRNA expression. Results. Treatment with resveratrol resulted in growth suppression and an increase in the cleavage of caspase-3 and PARP. A dose-dependent inhibition of ASCL1, a neuroedocrine transcription factor, was observed at the protein and mRNA levels. Protein levels of CgA, a marker of hormone secretion, were also reduced after treatment with resveratrol. A dose-dependent induction of Notch2 mRNA was observed by qPCR. Conclusions. Resveratrol suppresses in vitro growth, likely through apoptosis, as demonstrated by cleavage of caspase-3 and PARP. Furthermore, resveratrol decreased neuroedocrine markers ASCL1 and chromogranin A.
Induction of Notch2 mRNA suggests that this pathway may be central in the anti-MTC effects observed.
Medullary thyroid cancer (MTC) is derived from the calcitonin-producing parafollicular cells. This cancer accounts for 3 to 5% of thyroid cancer cases, although up to 14% of thyroid cancer deaths. 1 Although early total thyroidectomy may be potentially curative for familial cases of MTC, sporadic MTC accounts for approximately 75% of cases. Surgical resection in the patient population, however, results in a recurrence rate of almost 50%. Additionally, patients with MTC experience debilitating endocrinopathies, related to excessive hormone secretion. The acidic glycopeptide chromogranin A (CgA) is typically co-secreted with these hormones and is used as a clinical marker of the disease. [2] [3] [4] Traditional adjunctive therapies, including chemotherapy and radiotherapy, have shown limited efficacy, highlighting the need for novel therapeutic options. [5] [6] [7] [8] [9] Although the role of Notch as an oncogene is best defined in breast, colorectal, prostate, and pancreatic adenocarcinoma, the Notch signaling pathway has been shown to play a paradoxical tumor-suppressive role in neuroedocrine cancer types. 10 The Notch genes encode transmembrane receptors that regulate cellular differentiation, development, proliferation, and survival in many contexts. Upon binding of a ligand, a series of proteolytic cleavage steps occurs, and the Notch intracellular domain is released. This fragment translocates to the nucleus to activate a variety of target genes. In MTC cells, overexpression of Notch1 has been shown to inhibit growth and suppress achaete-scute complex-like 1 (ASCL1), an important helix-loop-helix transcription factor that regulates the neuroedocrine cancer phenotype and has been correlated with poor prognosis in neuroedocrine tumors.
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ASCL1 has been shown to play a particularly important role in the thyroid: ASCL1-null mice fail to develop parafollicular cells. 12, 13 Additionally, through ASCL1, Notch activation has been shown to suppress the levels of CgA. 3, 4 Work by our group and others has validated the Notch pathway as a tumor-suppressing pathway in MTC. Overexpression studies showed that Notch can suppress growth as well as ASCL1 expression. Pharmacologic induction of the Notch pathway was additionally shown to be a potent anti-MTC strategy in vitro. [14] [15] [16] This finding was subsequently confirmed in vivo. 17 Thus, drugs that target the Notch pathway are candidates for treatment of MTC.
Recently, our group developed a quantitative highthroughput screen to identify Notch-activating compounds. Pinchot et al. identified and validated resveratrol as a potential Notch activator in gastrointestinal and pulmonary carcinoid cells. Resveratrol treatment was shown to inhibit the growth of carcinoid cells both in vitro and in vivo while suppressing the expression of ASCL1, CgA, and serotonin. 18 Resveratrol is a dietary polyphenol found in the skins of grapes and peanuts. A growing body of evidence suggests that resveratrol may delay the onset of a variety of illnesses, including cancer, cardiovascular disease, and ischemic injuries. 19 High doses of resveratrol in vivo did not reveal any harmful alterations in hematology, clinical chemistry, and organ histopathology. 20 Currently, phase I/ II clinical trials of resveratrol are underway for the treatment of colorectal cancer and lymphoma. 21 In this study, we extended our analysis of resveratrol from carcinoid to MTC. We show that resveratrol suppresses growth, induces apoptosis, reduces ASCL1 and CgA expression, and increases Notch2 mRNA in MTC cells. To our knowledge, these results are the first description of a Notch2 activator in MTC and suggest that resveratrol may be a potential therapeutic option for MTC.
METHODS

Cell Culture
Human MTC (TT) cells were obtained from American Type Culture Collection (Manassas, VA) and maintained in RPMI 1640 (Invitrogen Life Technologies, Carlsbad, CA) supplemented with 16% fetal bovine serum (Sigma), 100 IU/ml penicillin, and 100 lg/ml streptomycin in a humidified atmosphere of 5% CO 2 in air at 37°C.
Cell Proliferation Assay
TT cell proliferation was measured by MTT (3-[4,5-dimethylthiazol-2-yl]-2,5 diphenyl tetrazolium bromide) assay as previously described. 13 Cells were seeded in quadruplicate into 24-well plates and were incubated overnight to allow cell adhesion. After incubation, cells were treated with 0 to 25 lM resveratrol (Biomol International, Plymouth Meeting, PA). Treatment medium was changed every 2 days with new dilutions of drug. To perform the MTT assay, cells were washed with phosphatebuffered saline and incubated in 250 ll of serum-free RPMI 1640 containing 0.5 mg/ml MTT for 4 h. After incubation, 750 ll of dimethyl sulfoxide (Fisher Scientific, Pittsburgh, PA) was added to each well and mixed thoroughly. Absorbance at 540 nm was measured with a spectrophotometer (lQuant; Bio-Tek Instruments, Winooski, VT) and plotted as an average ± standard error of the mean.
Immunoblotting
TT cells were incubated overnight to allow cell adhesion. After incubation, cells were treated for 2 days with varying doses of resveratrol. Total protein was collected as previously described and quantified with the BCA Protein Assay Kit (Thermo Scientific, Waltham, MA) according to the manufacturer's instructions. 13 Denatured cellular extracts were resolved on a 10% sodium dodecyl sulfatepolyacrylamide gel electrophoresis gel, transferred onto nitrocellulose membranes (Bio-Rad Laboratories, Hercules, CA), and blocked in milk. Membranes were incubated overnight in primary antibodies with the following dilutions: 1:2000 for mammalian achaete scute homologue-1 for ASCL1 (BD PharMingen, San Diego, CA); 1:500 for CgA (Zymed Laboratories, San Francisco, CA); 1:1000 for poly-ADP ribose polymerase (PARP), caspase 3, and cleaved caspase 3 (Cell Signaling Technology, Beverly, MA); and 1:10,000 for glyceraldehyde-3-phosphate dehydrogenase (GAPDH) (Trevigen, Gaithersburg, MD). Membranes were then incubated in appropriate amounts of horseradish peroxidase-conjugated goat anti-mouse or anti-rabbit antibody (Cell Signaling Technology), which were detected by Immun-star (Bio-Rad) or Supersignal West Femto (Pierce Protein Research Products, Rockford, IL) kits, according to the manufacturer's instructions.
Quantitative Real-Time Polymerase Chain Reaction
To quantify mRNA expression, we used quantitative real-time polymerase chain reaction (qPCR). After treatment as above, total RNA was isolated with the RNeasy Mini kit (Qiagen, Valencia, CA) according to the manufacturer's instructions. The iScript cDNA Synthesis Kit (Bio-Rad) was used to synthesize cDNA using 2 lg of RNA per sample. Amplification and detection of PCR products were performed with iQ SYBR Green (Bio-Rad).
The following PCR primer pairs were used: Notch2 
-Ct(target)), as described in the Real-Time PCR Applications Guide (Bio-Rad). Expression in treatment groups was compared to control expression and plotted as an average ± standard error of the mean.
Statistical Analysis
Statistical analysis was conducted by one-way analysis of variance (SPSS software, version 10.0; SPSS, Chicago, IL). A P value of \0.05 was considered statistically significant.
RESULTS
Resveratrol Inhibits MTC Proliferation
Human MTC cells were treated for up to 6 days with increasing doses of resveratrol and the MTT assay performed after 4 and 6 days of treatment. Compared to control, 25, 50, and 100 lM resveratrol treatments for 4 days reduced growth by 5, 8.9, and 16.4%, respectively (P \ 0.05). Treatment for 6 days resulted in a 19, 38, and 38% suppression of growth, respectively (P \ 0.002) (Fig. 1) .
Resveratrol Induces Cleavage of Apoptotic Markers
To explore the mechanism of resveratrol-induced growth suppression, we examined cleaved caspase 3 and cleaved poly-ADP ribose polymerase (cl-PARP) by Western blot testing. The intrinsic and extrinsic apoptotic pathways both result in the cleavage of caspase 3, a critical protease that cleaves other apoptotic proteins such as poly-ADP ribose polymerase (PARP) to promote cell death. Thus, increased cleavage of caspase 3 and PARP suggest activation of apoptotic pathways. [22] [23] [24] We found that treatment with resveratrol resulted in increased levels of both cleaved caspase 3 and cl-PARP. We also probed for full-length caspase 3 and PARP to verify that increased cleaved caspase 3 and cl-PARP are attributable to proteolytic cleavage, as opposed to an increase in total protein expression (Fig. 2) .
Resveratrol Suppresses Markers of MTC
We hypothesized that MTC growth inhibition would be associated with a change in neuroedocrine markers. Thus, we examined levels of ASCL1 and CgA, both important markers of MTC. [2] [3] [4] 11 we found that treatment of resveratrol resulted in a dosedependent reduction in CgA after 2 days of treatment (Fig. 3a) . This finding is notable because CgA is cosecreted with bioactive hormones and used as a clinical marker of disease. 2, 4 ASCL1 is transcription factor that is highly expressed in MTC and is strongly correlated with levels of CgA. 13 Furthermore, elevated ASCL1 protein is associated with poor prognosis in related neuroendocrine tumors. 25, 26 Thus, we performed Western blot analysis for ASCL1 and found that resveratrol suppressed ASCL1 protein levels after 2 days of treatment (Fig. 3a) .
Because ASCL1 suppression could occur at a number of levels, we performed qPCR for ASCL1 mRNA. Treatment with resveratrol resulted in a dose-dependent inhibition of ASCL1 mRNA levels. Notably, a 70% reduction in ASCL1 mRNA levels was achieved with 100 lM treatment of resveratrol (P \ 0.001) (Fig. 3b) .
Resveratrol Induces Notch2 mRNA
Previous studies have attributed growth inhibition, induction of apoptosis, and suppression of MTC markers to Notch pathway activation. 27 Thus, we investigated the effects of resveratrol on Notch2 mRNA expression by qPCR. Treatment with resveratrol resulted in a dosedependent induction of Notch2 mRNA expression, with a significant 15-fold induction with the 100 lM dose (P \ 0.001) (Fig. 4) . We also examined mRNA expression of other Notch isoforms and did not observe an induction (data not shown).
DISCUSSION
MTC is more difficult to treat and results in more deaths than other forms of thyroid cancers. 28 In addition to a high mortality rate, MTC is associated with debilitating symptoms such as dyspnea, dysphagia, diarrhea, and flushing, associated with increased levels of hormone secretion and CgA. 2, 10 Because surgery is the only curative option and traditional chemotherapy and radiotherapy have limited efficacy, novel therapeutic approaches are necessary.
The Notch1 pathway has been validated as a tumor suppressor in MTC and has been shown to suppress ASCL1 and CgA expression. 13 Previous studies by our group and others have shown that targeting the Notch1 pathway in vitro and in vivo is a potential anti-MTC strategy. 16, 17 Importantly, there seems to be marked overlap in the molecular targets of Notch1 and Notch2. 29 18 We extend our group's previous work with resveratrol here by examining the effects of resveratrol in MTC.
Our study showed that resveratrol is able to greatly suppress the in vitro proliferation of MTC cells after just 4 days of treatment. Although the degree of growth suppression was modest, the effect on neuroendocrine markers was substantial. Additionally, we demonstrate an increased cleavage in apoptotic markers, suggesting that induction of apoptosis is the mechanism of growth inhibition. Western blot analysis revealed suppression of CgA, a marker of hormone secretion. These data suggest the resveratrol is capable of suppressing bioactive hormones implicated in the debilitating endocrinopathies associated with MTC. We show that resveratrol suppresses the protein and mRNA levels of ASCL1, a transcription factor that is critical in normal parafollicular cell development. ASCL1 is also correlated with poor prognosis in neuroendocrine tumors and is a known mediator of CgA expression in MTC. 1, 4, 10, 12, 13, 30 We additionally show that these changes are associated with an induction of Notch2, a tumor-suppressing pathway in MTC.
In this study, we demonstrate the anti-MTC potential of resveratrol and provide what is to our knowledge the first description of a pharmacologic Notch2-inducing compound in MTC. Resveratrol is a naturally occurring compound with an established safety profile. [19] [20] [21] Given the demonstrated efficacy in vitro and known in vivo safety profile, resveratrol is worthy of additional preclinical investigation.
